Prognostic value of PCSK9 levels in patients with acute coronary syndromes. - Wikidata - awgldk - TriplyDB

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

http://www.wikidata.org/entity/Q41061002

about

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.PCSK9 and Atherosclerosis - Lipids and Beyond.The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.The Role of Inflammation in Cardiovascular Outcome.Lipoprotein(a): the revenant.Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes.[Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update].High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies.Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort.Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score.Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.Circulating PCSK9 is lowered acutely following surgery.Association of Level of Proprotein Convertase Subtilisin/Kexin Type 9 with Intima-Media Thickness in Patients with Familial Hypercholesterolemia.Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice.Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction Response: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)

P2860

Q33599961-3A259D47-52FC-436C-9177-F94949E174CC Q33675963-5382985B-49A5-4308-A317-6E1158253D47 Q38637552-E2AB4B41-6F0B-4870-8319-1CB4905EE0C3 Q39134471-19DC9257-6571-4AAE-8FB0-EF8DDEB8B24B Q40280257-B723C2A8-C4DE-4E6F-A649-C8BD60254A81 Q40530815-2F41BF4F-3C2E-46F9-A8A2-DB997D1A75E8 Q40740507-D2CEBE97-9D47-44B7-8B56-D0407CE17260 Q47139387-2F8F40C5-0563-46B2-B3A4-AD74825D8D30 Q47390481-8FAD3A5A-5628-46C9-BF4D-039C488CC359 Q47597427-2F9C4546-0147-4152-BA10-E16AC8EBB004 Q47613511-92D55DEF-EDEB-4989-9F22-294B0CE698FB Q48178320-E515EC74-57B2-4EEA-BD9A-5A0F5E4FF45F Q48284544-343A0B13-D324-4276-9487-19A331839BB0 Q50880816-AF7D6C3B-B223-4492-B873-A8FCF84373A6 Q52838034-9C77C46F-8C67-4505-AEA6-2D383F6355BD Q53337735-FB04DEE8-4362-4D0D-8EDF-C5C97C264A7D Q54940707-D08621E5-BDE3-485E-9756-E526E481BA12 Q55383088-4E77037B-D59C-4FF9-AB1E-26423F68CA6E Q57821404-DAF7AAC9-D3D6-4801-B48D-C35DAD054D47 Q58724610-FF8288B7-8D37-42F6-8B64-FB4902F1345D Q58730027-98B50A1B-FC4A-4BD7-8A3C-D39FEFDA9D83 Q58730050-EE6E33E0-B062-4695-A245-38DF8DDDB87F

P2860

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

http://www.wikidata.org/entity/Q41061002

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

@en

type

label

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

@en

prefLabel

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

@en

P1433

Q41061002-CAA5A173-8278-4641-8C3B-45FB46B7CA75

P1476

Q41061002-E64FDDC5-D485-4B54-9FE5-1747BADFE89C

P2093

Q41061002-187F7994-8781-4946-A94C-063C5A0B7B82

Q41061002-55E7794F-29BD-4BD4-B1A5-66F4B9405EAD

Q41061002-68007EF8-18FC-471E-8F78-9313891FE896

Q41061002-69494642-61CB-44B2-848A-377D819D853C

Q41061002-792AAAF5-A969-4E7A-B4ED-77F55BA9C6A2

Q41061002-91118743-EC60-4CDE-82D0-3D8513454E96

Q41061002-A6C35203-91B5-4F24-92BD-B3361A96AA62

Q41061002-BB07218B-1BA6-4DD2-928C-3A04A405F785

Q41061002-BDEB06B4-DBC5-4020-80D4-53D5122DB871

P2860

Q41061002-0140CF05-EE6D-41F8-8BE1-46FC3113A622

Q41061002-01BF66A0-9456-4AEC-8044-AF74AA76B4D6

Q41061002-04FC4212-B423-48D2-86C2-A330511F555F

Q41061002-0C0DE73D-E656-481A-9684-258DE5026613

Q41061002-2A996DDC-C32D-4289-8000-DFA438390ADE

Q41061002-47EB6B15-9D24-4CD9-9337-A65F162A5734

Q41061002-55D195FB-3B2A-4688-B4D7-2E62311DE54D

Q41061002-58707E28-4954-425A-A427-6C65E7089C2E

Q41061002-5BB9A2E3-1274-447B-9C0D-B676E770EAB5

Q41061002-60F46A81-CA14-4BD0-9EB8-6231C7855674

P304

Q41061002-3A353211-B7D7-4B5A-8A23-E735B0220519

P31

Q41061002-BF466BF3-9112-4827-AE27-817A3807FAA3

P356

Q41061002-E94B92AB-23FA-4397-BA28-F8B8967082EF

P433

Q41061002-2AD88DB1-AD5A-452A-8BF6-7B5CFC681A84

P478

Q41061002-B9D1F2B2-6018-43E3-B604-4344390576C2

P50

Q41061002-2BD3B7CF-728B-4617-A40B-EFDD4BD203FC

Q41061002-48395F66-731D-4F6B-9FFC-49A686B37D64

Q41061002-87148D0F-1E37-4F4C-8A73-8A01C25E34D6

Q41061002-88BF2726-E788-4BB4-8CB3-B4206C400D56

Q41061002-AD7FAC1E-5E56-43BA-8170-A49F372F5CDC

Q41061002-BD9A659B-36CB-4B9C-B4AC-9122D306F684

Q41061002-F9CBDA17-8958-4629-B45A-8B8F3B1A75D1

P577

Q41061002-1A288536-82A3-40D6-8506-17CEAEF446C7

P698

Q41061002-E7BB902B-6260-4E4E-ABBE-FBF22E9B85DC

P356

P1433

European Heart Journal

P1476

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

@en

P2093

Baris Gencer

http://www.w3.org/2001/XMLSchema#string

Christian M Matter

http://www.w3.org/2001/XMLSchema#string

Dik Heg

http://www.w3.org/2001/XMLSchema#string

François Mach

http://www.w3.org/2001/XMLSchema#string

Nicolas Rodondi

http://www.w3.org/2001/XMLSchema#string

Nicolas Vuilleumier

http://www.w3.org/2001/XMLSchema#string

Reto Auer

http://www.w3.org/2001/XMLSchema#string

Roland Klingenberg

http://www.w3.org/2001/XMLSchema#string

Soheila Aghlmandi

http://www.w3.org/2001/XMLSchema#string

P2860

The PCSK9 decade

PCSK9: a key modulator of cardiovascular health

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

P304

546-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHV637

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Fabrizio Montecucco

Federico Carbone

Thomas Lüscher

Stephan Windecker

P577

2015-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26655339

http://www.w3.org/2001/XMLSchema#string